B2s Life Sciences
B2s Life Sciences is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma
Sponsor Aura Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
Sponsor Abcuro Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available7 trial-level findings · Read insights
- Enrollment was concentrated in the United States (224/272 participants), while 24 participants were enrolled in the EEA, including Belgium (4), Germany (4), and France (5).
- A sentinel cohort was added, and initiation of Part B enrollment was contingent on a favorable DSMB review of Part A safety and tolerability data.
- The screening period was extended to up to 35 days and the upper body-weight limit was increased by protocol amendment.
- Eligibility criteria were revised to permit participants with non-clinically significant bundle branch block, clarify malignancy and monoclonal-protein restrictions, and remove exclusion for a positive urine drug test.
- A France-specific exclusion criterion was added for persons under court protection, persons not affiliated with a social security system, and protected adults.
- The protocol clarified mTUG eligibility requirements and allowed investigator or medical-monitor assessment of whether concomitant autoimmune disease could confound clinical assessments.
- The Week 80 safety follow-up visit could be conducted by telephone after protocol amendment.
These findings describe the trial, not the service provider’s performance or responsibility.
A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label, Multicenter Study to Evaluate the Long-term Safety and Efficacy of Ulviprubart (ABC008) in Subjects Who Have Completed a Trial of Ulviprubart for the Treatment of Inclusion Body Myositis
Sponsor Abcuro Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People with Cystic Fibrosis
Sponsor Arcturus Therapeutics Europe B.V.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for B2s Life Sciences?
The 2026-10-09 snapshot links B2s Life Sciences to 8 distinct CTIS trials. Recorded services include Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for B2s Life Sciences?
The most frequently recorded therapeutic areas are Hepatology, Immunology, Infectious Disease, Musculoskeletal. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to B2s Life Sciences conducted?
The linked trials record locations in 16 countries, including Germany, France, Belgium, Austria, Czechia. These are trial locations, not confirmed office locations or countries where B2s Life Sciences delivered services.
What can this page tell me about B2s Life Sciences's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under B2s Life Sciences. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- B2S Life Sciences LLC
- B2s Life Sciences LLC